{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.68","upperLimit":"11.99","value":"6.77"},{"groupId":"OG001","lowerLimit":"2.60","upperLimit":"24.41","value":"11.17"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"description":"Overall survival (OS) was analyzed and reported for both PCNSL and PTL patient populations.\n\nOS is defined as the time from first dosing date to the date of death. For participants without documentation of death, OS will be censored on the last date the participant was known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab dosed to participants with relapsed/refractory Primary Central Nervous System Lymphoma (PCNSL).\n\nNivolumab 240 mg was given every 2 weeks for 8 cycles. Beginning with Cycle 9, nivolumab 480 mg was given every 4 weeks for a total therapy duration of 2 years, or until progressive disease, unacceptable toxicity, or withdrawal of consent. Nivolumab was administered as a 30-minute infusion.","id":"OG000","title":"PCNSL Cohort"},{"description":"Nivolumab dosed to participants with relapsed/refractory Primary Testicular Lymphoma (PTL).\n\nNivolumab 240 mg was given every 2 weeks for 8 cycles. Beginning with Cycle 9, nivolumab 480 mg was given every 4 weeks for a total therapy duration of 2 years, or until progressive disease, unacceptable toxicity, or withdrawal of consent. Nivolumab was administered as a 30-minute infusion.","id":"OG001","title":"PTL Cohort"}],"paramType":"MEDIAN","populationDescription":"All treated PCNSL and PTL participants","reportingStatus":"POSTED","timeFrame":"Up to approximately 51 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}